Updated June 22, 2012, at 6:00 p.m. EST: This brief erroneously stated that viruses were discovered on CareFusion’s respiratory software systems. The malicious code was found on the website that houses the software updates, not in the software itself.
CareFusion Corp.
CareFusion hits 52-week high on Q3 results | Earnings Roundup
CareFusion (NYSE:CFN) hit a 52-week high Friday after beating Wall Street boffins’ predictions for its 3rd-quarter earnings and raising its full-year revenue guidance.
The San Diego-based medical device maker reported profits of $31 million, or 13¢ per diluted share, on sales of $919 million during the 3 months ended March 31, a top-line gain of 9.1%.
MassDevice.com +3 | The top 3 med-tech stories for April 23, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
CareFusion hands neurodiagnostics unit to Natus Medical for $58M
Medical Device Tax: Ten companies in line for a whack
The medical device tax set to take effect next year as part of the Affordable Care Act will see all medical device companies pay a 2.3% levy on U.S. sales. But the tax is likely to strike some companies a lot harder where it hurts the most: the bottom line.
CareFusion lands 510(k) for next-gen electrodiagnostic system | Regulatory Roundup
Report: J&J set for EU OK on Synthes buyout | Wall Street Beat
European Union regulators are poised to give the OK to Johnson & Johnson‘s (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters.
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Moody’s estimates med-tech tax impact
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.
The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody’s, with organic growth rates of between 2% and 3% during that period.
St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat
Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”
STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.